58. 肥大型心筋症 Hypertrophic cardiomyopathy Clinical trials / Disease details
臨床試験数 : 119 / 薬物数 : 163 - (DrugBank : 45) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 161
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02291237 (ClinicalTrials.gov) | February 5, 2015 | 11/11/2014 | Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy | Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy | Hypertrophic Cardiomyopathy | Drug: Eleclazine;Drug: Placebo | Gilead Sciences | NULL | Terminated | 18 Years | 65 Years | All | 172 | Phase 2/Phase 3 | United States;Australia;France;Germany;Israel;Italy;Netherlands;United Kingdom |